GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » DermTech Inc (NAS:DMTK) » Definitions » ROC (Joel Greenblatt) %

DermTech (DermTech) ROC (Joel Greenblatt) % : -137.15% (As of Dec. 2023)


View and export this data going back to 2017. Start your Free Trial

What is DermTech ROC (Joel Greenblatt) %?

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. DermTech's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -137.15%.

The historical rank and industry rank for DermTech's ROC (Joel Greenblatt) % or its related term are showing as below:

DMTK' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -3878.43   Med: -815.16   Max: -173.76
Current: -173.76

During the past 8 years, DermTech's highest ROC (Joel Greenblatt) % was -173.76%. The lowest was -3878.43%. And the median was -815.16%.

DMTK's ROC (Joel Greenblatt) % is ranked worse than
74.14% of 232 companies
in the Medical Diagnostics & Research industry
Industry Median: -13.89 vs DMTK: -173.76

DermTech's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 32.80% per year.


DermTech ROC (Joel Greenblatt) % Historical Data

The historical data trend for DermTech's ROC (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

DermTech ROC (Joel Greenblatt) % Chart

DermTech Annual Data
Trend Mar16 Mar17 Mar18 Mar19 Dec20 Dec21 Dec22 Dec23
ROC (Joel Greenblatt) %
Get a 7-Day Free Trial -3,878.43 -1,292.16 -1,030.32 -316.48 -174.22

DermTech Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
ROC (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -251.21 -207.67 -212.57 -133.89 -137.15

Competitive Comparison of DermTech's ROC (Joel Greenblatt) %

For the Diagnostics & Research subindustry, DermTech's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


DermTech's ROC (Joel Greenblatt) % Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, DermTech's ROC (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where DermTech's ROC (Joel Greenblatt) % falls into.



DermTech ROC (Joel Greenblatt) % Calculation

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:

ROC (Joel Greenblatt) %=EBIT/Average of (Net fixed Assets + Net Working Capital)

EBIT stands for Earnings Before Interest and Taxes.

Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.

GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.

Working Capital(Q: Sep. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(3.605 + 1.196 + 2.928) - (2.669 + 0.236 + 6.753)
=-1.929

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(2.584 + 1.004 + 2.3) - (5.623 + 0.196 + 4.542)
=-4.473

When net working capital is negative, 0 is used.

So ROC (Joel Greenblatt) % of DermTech for the quarter that ended in Dec. 2023 can be restated as:

ROC (Joel Greenblatt) %(Q: Dec. 2023 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Sep. 2023  Q: Dec. 2023
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-79.008/( ( (58.5 + max(-1.929, 0)) + (56.71 + max(-4.473, 0)) )/ 2 )
=-79.008/( ( 58.5 + 56.71 )/ 2 )
=-79.008/57.605
=-137.15 %

Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


DermTech  (NAS:DMTK) ROC (Joel Greenblatt) % Explanation

The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.

Joel Greenblatt uses his definition of Return on Capital and Earnings Yield (Joel Greenblatt) % to rank companies.


DermTech ROC (Joel Greenblatt) % Related Terms

Thank you for viewing the detailed overview of DermTech's ROC (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.


DermTech (DermTech) Business Description

Traded in Other Exchanges
N/A
Address
11099 N. Torrey Pines Road, Suite 100, La Jolla, CA, USA, 92037
DermTech Inc is an emerging growth molecular diagnostic company. The company is engaged in marketing and developing novel non-invasive genomic tests to aid in the diagnosis of various skin conditions, including skin cancer, inflammatory diseases, and aging-related conditions. While the company generates revenue through laboratory services.
Executives
Kevin M Sun officer: Chief Financial Officer 6340 SEQUENCE DRIVE, SAN DIEGO CA 92121
Claudia Ibarra officer: Chief Operating Officer C/O DERMTECH, INC., 11099 N. TORREY PINES ROAD, SUITE 100, LA JOLLA CA 92037
Ramin Akhavan officer: General Counsel C/O DERMTECH, INC., 11099 N. TORREY PINES ROAD, SUITE 100, LA JOLLA CA 92037
Mark Bryan Aguillard officer: Chief Commercial Officer 19800 CORDILL LANE, SPICEWOOD TX 78669
Todd Michael Wood officer: Chief Commercial Officer C/O OBALON THERAPEUTICS, INC., 5421 AVENIDA ENCINAS, SUITE F, SAN DIEGO CA 92008
Bret Christensen director, officer: Chief Executive Officer 600 TECHNOLOGY PARK DRIVE, SUITE 200, BILLERICA MA 01821
John Dobak director, officer: Chief Executive Officer 11099 N. TORREY PINES ROAD, SUITE 100, LA JOLLA CA 92037
Rtw Investments, Lp 10 percent owner 40 10TH AVENUE, 7TH FLOOR, NEW YORK NY 10014
Kirk Malloy director 5200 ILLUMINA WAY, SAN DIEGO CA 92122
Mark Christopher Capone director 320 WAKARA WAY, SALT LAKE CITY UT 84108
Herm Rosenman director OXFORD IMMUNOTEC GLOBAL PLC, 94C INNOVATION DRIVE, HILTON PARK, SAN DIEGO X0 OX14 4RZ
Nathalie Gerschtein Keraudy director C/O DERMTECH, INC., 11099 N. TORREY PINES ROAD, SUITE 100, LA JOLLA CA 92037
Monica Tellado director C/O DERMTECH, INC., 11099 N. TORREY PINES ROAD, SUITE 100, LA JOLLA CA 92037
Enrico Picozza director 11099 N. TORREY PINES ROAD, SUITE 100, LA JOLLA CA 92037
Matthew L. Posard director 11099 N. TORREY PINES ROAD, SUITE 100, LA JOLLA CA 92037